Aurora Cannabis Inc.

NASDAQ:ACB

Drug Manufacturers - Specialty & Generic

Healthcare
$4.40 +0.51%

+$0.02 today

Market cap
$289.28M
Beta
1.34
P/E (TTM)
-3.2
EPS (TTM)
-$1.31
52W Low $2.73High $6.67

Volume 0.92M

Average 1.00M

ACB Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Aurora Cannabis Inc.NASDAQ: ACB

Revenue · Q4 FY2026 · quarter ended Mar 2026

Revenue declines year over year

Q4 FY2026 revenue of CA$38.11M fell 57.9% year over year, behind the -9.4% change in trailing-twelve-month revenue. Sequentially, it fell 59.5% from the prior quarter. Over 3 fiscal years it compounded at +12.8% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 3 analysts of CA$313.92M (-2.3%) for the fiscal year ending Mar 2027, a step up from the -6.4% reported in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$38.11M-59.5% QoQ
Last fiscal yearMar 2026
CA$321.42M-6.4% YoY
LTMMar 2026
CA$310.87M-9.4% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-57.9%-23.5%+34.4 pp
1 year-6.4%-2.3%+4.0 pp
3-year CAGR+12.8%+6.1%-6.7 pp
5-year CAGR+8.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

CAD · from the income statement

Latest · FY2026
321.42M CAD
Year-over-year change
-6.4%
4-year CAGR
+9.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How ACB compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -9.4% is the 9th highest of 10, against a peer median of +13.8%.
  • Over three fiscal years its annual growth of +12.8% compares with a peer median of +9.1%.
ACB Competitors
Revenue for ACB and competitors
Company Period LTM YoY 3-year CAGR
HITIHigh Tide Inc.LTM Apr 2026CA$671.57M CAD+22.0%+18.5%
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$361.51M USD+13.8%-10.3%
CGCCanopy Growth CorporationLTM Mar 2026CA$312.34M CAD+16.1%+13.2%
ACBAurora Cannabis Inc.LTM Mar 2026CA$310.87M CAD-9.4%+12.8%
OGIOrganigram Global Inc.LTM Mar 2026CA$274.13M CAD+41.2%—
LFMDLifeMD, Inc.LTM Mar 2026$219.42M USD-6.2%+17.7%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$135.16M USD—+5.0%
TKNOAlpha Teknova, Inc.LTM Mar 2026$41.8M USD+9.3%-0.7%
EDITEditas Medicine, Inc.LTM Mar 2026$38.69M USD+8.0%+27.1%
BIOABioAge Labs, Inc.LTM Mar 2026$10.32M USD+611.0%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$8.37M USD-52.9%-35.9%
Peer median (excluding ACB) —+13.8%+9.1%

Competitors are the stored peer set for ACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2022
Jun 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue221.34M223.8M270.28M343.29M321.42M
Cost of Revenue200.11M209.02M138.82M155.69M304.67M
Gross Profit21.23M14.78M131.46M187.61M16.75M
Gross Margin9.6%6.6%48.6%54.6%5.2%
Research & Development10.39M5.77M3.57M3.68M6.01M
Selling, General & Admin188.99M170.48M156.88M166.47M173.95M
Operating Expenses252.67M221.98M177.91M182.66M179.96M
Depreciation & Amortization93.66M52.59M33.07M22.55M14.23M
EBITDA(1.55B)(135M)(12.34M)51.35M(148.99M)
EBITDA Margin-702.4%-60.3%-4.6%15.0%-46.4%
Operating Income(231.45M)(207.19M)(46.45M)4.95M(163.21M)
Operating Margin-104.6%-92.6%-17.2%1.4%-50.8%
Interest Income4.51M19M12.81M11.51M5.86M
Interest Expense71.81M39.46M14.19M8.42M1.81M
Other Income / Expenses(1.49B)(576.51M)(13.15M)15.43M106.54M
Income Before Tax(1.72B)(783.7M)(59.6M)20.38M(56.67M)
Pre-Tax Margin-777.1%-350.2%-22.1%5.9%-17.6%
Income Tax Expense(2.14M)16.55M(554K)4.62M2.1M
Net Income(1.72B)(816.63M)(69.33M)1.59M(122.07M)
Net Margin-776.0%-364.9%-25.6%0.5%-38.0%
EPS (Basic)(79.92)(8.17)(1.28)0.03(2.15)
EPS (Diluted)(79.92)(8.17)(1.28)0.03(2.15)
Weighted Avg Shares21.49M32.27M51.26M54.88M56.71M
Weighted Avg Shares (Diluted)21.49M32.27M51.26M55.75M56.71M

Aurora Cannabis Inc.

NASDAQ:ACB

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.